TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04802356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first
Study: NCT06361446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT04802356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT)
Description: High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
Study: NCT05615701

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOSedge imaging
Description: Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
Study: NCT06567106

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound application
Description: Apply ultrasound to the participant within a safe range.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound application
Description: Apply ultrasound to the participant within a safe range.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound application
Description: Apply ultrasound to the participant within a safe range.
Study: NCT05004649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysical task
Description: A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
Study: NCT06535932

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amara View Minimal Contact Full Face Mask
Description: The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F40 Minimal Contact Full Face Mask
Description: The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
Study: NCT05999916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Miamind Neurostimulator
Description: 60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
Study: NCT04899934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile and technology assisted aftercare
Description: The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
Study: NCT05856760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Target dose of 400 mg daily
Study: NCT05440968

Intervention type: OTHER
Group type: OTHER
Intervention: Point of Care - Glycated Hemoglobin (A1c)
Description: Test for diagnosis of Diabetes through a Point of care device

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: Routinary diagnosis diabetes test by venous blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: Routinary diagnosis diabetes test by venous blood sample
Study: NCT05073523

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
Study: NCT05579262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
Study: NCT05215496

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-PEG-folate PET/CT scan
Description: A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
Study: NCT06050239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-0057
Description: The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
Study: NCT05281354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
Study: NCT00625157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF 1096 0.5 % cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF 1096 placebo cream
Study: NCT05283954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination regimen: Fluoxetine, Prednisolone, Ivermectin
Description: Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days.

Intervention type: DRUG
Group type: OTHER
Intervention: Combination regimen: Albendazole, Vitamin C
Description: Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days.
Study: NCT05220410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open-Label
Study: NCT06154993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: static opening with slider+ Conventional PT
Description: Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic opener with slider + Conventional PT
Description: Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins
Study: NCT06229314

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training
Description: In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
Study: NCT04943549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
Study: NCT04939090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05402345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlcNAc-GlcN
Description: GlcNAc powder - weight-dependent dose
Study: NCT05783089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-mesothelin CAR-T cells
Description: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
Study: NCT04961515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the DLT is not found, the dose of 250mg qd will be used for phase II trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks
Study: NCT05972590

Intervention type: OTHER
Group type: OTHER
Intervention: Biological samples collection (blood + feces)
Description: Blood + stools samples will be collected from each volunteer
Study: NCT05402345

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo xylose
Study: NCT06567106

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No ultrasound application
Description: No ultrasound application to the participant.
Study: NCT05673603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet
Study: NCT04638127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREEMIE PROGRESS
Description: PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: usual care and welcome videos
Study: NCT04920695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Pulmonary vasodilator (gas).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: medical grade normoxic gas (FiO2 = 0.21)
Study: NCT05612958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKM-410
Description: Injection up to 2.0ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm ULTRA PLUS XC 1.0ml
Description: Injection up to 2.0ml
Study: NCT05356169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: with or without venetoclax
Description: Bcl-2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: with or without venetoclax
Description: Bcl-2 inhibitor
Study: NCT05022992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
Study: NCT05547971

Intervention type: RADIATION
Intervention: intensity-modulated radiation therapy
Description: The patients got intensity-modulated radiation therapy during observation

Intervention type: RADIATION
Intervention: intensity-modulated radiation therapy
Description: The patients got intensity-modulated radiation therapy during observation
Study: NCT05249777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0069 hard capsule
Description: TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD0069 Placebo
Description: TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
Study: NCT05026229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib plus consolidation chemotherapy with vincristine and prednisone
Description: After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
Description: After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.